| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Athe Tsibris | |
| Sara Gianella | |||
| Catherine Godfrey | |||
| Liz Barr | |||
| P2860 | cites work | Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection | Q73386724 |
| Initial plasma HIV-1 RNA levels and progression to AIDS in women and men | Q73583102 | ||
| Gender differences in virologic response to treatment in an HIV-positive population: a cohort study | Q73594410 | ||
| Expansion of CD4+CD25+and FOXP3+ regulatory T cells during the follicular phase of the menstrual cycle: implications for human reproduction | Q79718078 | ||
| Induction of regulatory T cells by physiological level estrogen | Q80678123 | ||
| X-inactivation profile reveals extensive variability in X-linked gene expression in females | Q22122481 | ||
| The evolving epidemiology of HIV/AIDS | Q22242700 | ||
| The Xs and Y of immune responses to viral vaccines | Q24706476 | ||
| Early Defensive Mechanisms against Human Papillomavirus Infection | Q26852611 | ||
| Self-Collected versus Clinician-Collected Sampling for Chlamydia and Gonorrhea Screening: A Systemic Review and Meta-Analysis | Q27025596 | ||
| Immune cells in the female reproductive tract | Q28086783 | ||
| Vaginal microbiome of reproductive-age women | Q28284755 | ||
| Effect of tamoxifen on regulation of viral replication and human immunodeficiency virus (HIV) long terminal repeat-directed transcription in cells chronically infected with HIV-1 | Q28332975 | ||
| Recovery of replication-competent HIV despite prolonged suppression of plasma viremia | Q29615995 | ||
| Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection | Q29619738 | ||
| Progestin-Containing Contraceptives Alter Expression of Host Defense-Related Genes of the Endometrium and Cervix | Q30358037 | ||
| Sex differences in nevirapine rash | Q31704898 | ||
| Comparison of self-collected and physician-collected vaginal swabs for microbiome analysis | Q33536622 | ||
| Type-specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections | Q33553333 | ||
| 17β-estradiol protects primary macrophages against HIV infection through induction of interferon-alpha | Q33631612 | ||
| Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. | Q33649753 | ||
| Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues | Q33652519 | ||
| Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women | Q33686465 | ||
| Modulation of 17beta-estradiol on the number and cytotoxicity of NK cells in vivo related to MCM and activating receptors | Q38296538 | ||
| Hormonal modulation of the immune system - A spotlight on the role of progestogens | Q38362237 | ||
| Sex-driven differences in immunological responses: challenges and opportunities for the immunotherapies of the third millennium | Q38435403 | ||
| A Systematic Review of the Inclusion (or Exclusion) of Women in HIV Research: From Clinical Studies of Antiretrovirals and Vaccines to Cure Strategies | Q38584993 | ||
| Phytoestrogens mediated anti-inflammatory effect through suppression of IRF-1 and pSTAT1 expressions in lipopolysaccharide-activated microglia | Q39111345 | ||
| TLR7 ligands induce higher IFN-alpha production in females. | Q40247926 | ||
| Estradiol negatively regulates HIV-LTR promoter activity in glial cells | Q40290453 | ||
| Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy | Q40998951 | ||
| Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. | Q41880147 | ||
| How Might We Cure HIV? | Q42227337 | ||
| HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. | Q43130032 | ||
| Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years | Q43569408 | ||
| Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash | Q43652265 | ||
| Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women | Q43770289 | ||
| Enrollment of racial/ethnic minorities and women with HIV in clinical research studies of HIV medicines. | Q43904517 | ||
| Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team | Q44074077 | ||
| Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load | Q44314022 | ||
| Sex differences in HIV-1 viral load and progression to AIDS. | Q44567818 | ||
| Estrogen-mediated protection against HIV Tat protein-induced inflammatory pathways in human vascular endothelial cells | Q44934441 | ||
| Enrollment of women in National Heart, Lung, and Blood Institute-funded cardiovascular randomized controlled trials fails to meet current federal mandates for inclusion | Q45161542 | ||
| Estrogen stimulates transcription of human immunodeficiency virus type 1 (HIV-1). | Q45421017 | ||
| Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. | Q45746984 | ||
| Expression of membrane progesterone receptors on human T lymphocytes and Jurkat cells and activation of G-proteins by progesterone. | Q45958804 | ||
| Estradiol and progesterone regulate HIV type 1 replication in peripheral blood cells | Q46608228 | ||
| Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy | Q46791174 | ||
| Cervicovaginal microbiota: simple is better. | Q46832874 | ||
| Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study | Q37628108 | ||
| The X chromosome in immune functions: when a chromosome makes the difference | Q37774853 | ||
| Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract | Q37966624 | ||
| Low-level viraemia on HAART: significance and management | Q37966778 | ||
| Inclusion of minorities and women in cancer clinical trials, a decade later: Have we improved? | Q38106914 | ||
| Estrogen's effects in chronic autoimmune/inflammatory diseases and progression to cancer | Q38168954 | ||
| Influence of common mucosal co-factors on HIV infection in the female genital tract. | Q38195075 | ||
| Steroids and the blood-brain barrier: therapeutic implications | Q38259311 | ||
| Gender difference in CD4+ cell counts persist after HIV-1 infection. SEROCO Study Group. | Q50946624 | ||
| X-Chromosome complement and estrogen receptor signaling independently contribute to the enhanced TLR7-mediated IFN-α production of plasmacytoid dendritic cells from women. | Q51105373 | ||
| The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor α signaling. | Q51386967 | ||
| Effect of menstrual cycle variation in female sex hormones on cellular immunity and regulation. | Q51488407 | ||
| Estradiol-dependent perforin expression by human regulatory T-cells. | Q51629955 | ||
| Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trial. | Q51835167 | ||
| Biomedical research. Of mice and women: the bias in animal models. | Q53065986 | ||
| Sex bias in trials and treatment must end. | Q53068521 | ||
| Gender agenda: sex bias can be justified in animal research. | Q53069925 | ||
| Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. | Q53608173 | ||
| Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis. | Q53880710 | ||
| Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study | Q57180108 | ||
| HIV Persistence in the Gut Mucosa of HIV-Infected Subjects Undergoing Antiretroviral Therapy Correlates with Immune Activation and Increased Levels of LPS | Q57573965 | ||
| Access to Antiretroviral Treatment, Incidence of Sustained Therapy Interruptions, and Risk of Clinical Events According to Sex | Q57632363 | ||
| Do gender differences in CD4 cell counts matter? | Q73271751 | ||
| Hormonal milieu at time of B cell activation controls duration of autoantibody response | Q35300035 | ||
| Human adipose tissue as a reservoir for memory CD4+ T cells and HIV. | Q35318746 | ||
| Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract | Q35636288 | ||
| Sex differences in pharmacokinetics and pharmacodynamics | Q35639177 | ||
| Sex-based differences in immune function and responses to vaccination | Q35661949 | ||
| Inflammation and race and gender differences in computerized tomography-measured adipose depots | Q35707614 | ||
| Hydrogen Peroxide-Producing Lactobacilli Are Associated With Lower Levels of Vaginal Interleukin-1β, Independent of Bacterial Vaginosis | Q35903302 | ||
| Nuclear receptor, coregulator signaling, and chromatin remodeling pathways suggest involvement of the epigenome in the steroid hormone response of endometrium and abnormalities in endometriosis | Q35931083 | ||
| Characterization of the immune cell repertoire in the normal fallopian tube. | Q36198864 | ||
| Progesterone and autoimmune disease | Q36202227 | ||
| Dialogues on diversifying clinical trials: successful strategies for engaging women and minorities in clinical trials. | Q36204611 | ||
| 17beta-Estradiol utilizes the estrogen receptor to regulate CD16 expression in monocytes | Q36248880 | ||
| Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity | Q36294698 | ||
| Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission | Q36353342 | ||
| Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy | Q36499290 | ||
| Estrogen signaling multiple pathways to impact gene transcription | Q36499769 | ||
| Innate and adaptive anti-HIV immune responses in the female reproductive tract | Q36637034 | ||
| Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. | Q36824026 | ||
| The complex role of estrogens in inflammation. | Q36886660 | ||
| Persistent HIV-1 replication maintains the tissue reservoir during therapy | Q36897321 | ||
| Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review | Q36917426 | ||
| Estrogen and CD4+ T cells | Q36925326 | ||
| Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009. | Q36991121 | ||
| Association of genital human papillomavirus infection with HIV acquisition: a systematic review and meta-analysis | Q37030414 | ||
| 17β-Estradiol inhibits HIV-1 by inducing a complex formation between β-catenin and estrogen receptor α on the HIV promoter to suppress HIV transcription | Q37043012 | ||
| Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication. | Q37070383 | ||
| The sexually dimorphic role of adipose and adipocyte estrogen receptors in modulating adipose tissue expansion, inflammation, and fibrosis | Q37173351 | ||
| Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy | Q37200979 | ||
| Gender differences in the treatment of HIV infection | Q37245490 | ||
| The X-files in immunity: sex-based differences predispose immune responses | Q37252714 | ||
| Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women | Q37272371 | ||
| Stronger inflammatory/cytotoxic T-cell response in women identified by microarray analysis | Q37326860 | ||
| Policy: NIH to balance sex in cell and animal studies | Q37403351 | ||
| Phenotype and functionality of CD4+ and CD8+ T cells in the upper reproductive tract of healthy premenopausal women | Q37626039 | ||
| Estrogen receptor alpha inhibits the estrogen-mediated suppression of HIV transcription in astrocytes: implications for estrogen neuroprotection in HIV dementia | Q33686905 | ||
| Immune activation and HIV persistence: considerations for novel therapeutic interventions | Q33698781 | ||
| Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis | Q33821257 | ||
| PD-1, gender, and autoimmunity | Q33910421 | ||
| Reference ranges and sources of variability of CD4 counts in HIV-seronegative women and men. | Q33935910 | ||
| Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy | Q33962223 | ||
| Behavioral, biological, and demographic risk and protective factors for new HIV infections among youth in Rakai, Uganda | Q34040924 | ||
| Sex-based differences in HIV type 1 pathogenesis | Q34148475 | ||
| Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers | Q34189960 | ||
| Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis | Q34260259 | ||
| Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy | Q34384134 | ||
| CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells | Q34395160 | ||
| Sex bias in neuroscience and biomedical research | Q34433270 | ||
| Estrogen enhances immunoglobulin production by human PBMCs | Q34491431 | ||
| Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. | Q34495619 | ||
| Human papillomavirus seropositivity and subsequent risk of HIV acquisition in rural South African women | Q34551969 | ||
| Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals | Q34561005 | ||
| Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women | Q34568436 | ||
| Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy | Q34588169 | ||
| Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial | Q34664004 | ||
| HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells | Q34672568 | ||
| Does patient sex affect human immunodeficiency virus levels? | Q34736412 | ||
| Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women | Q34737260 | ||
| Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection | Q34764377 | ||
| Early HIV-1 target cells in human vaginal and ectocervical mucosa | Q34796617 | ||
| Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review | Q34870233 | ||
| Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. | Q34981137 | ||
| Innate and adaptive immunity at mucosal surfaces of the female reproductive tract: stratification and integration of immune protection against the transmission of sexually transmitted infections | Q34982527 | ||
| Raltegravir concentrations in the genital tract of HIV-1-infected women treated with a raltegravir-containing regimen (DIVA 01 study) | Q35005146 | ||
| Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy | Q35077988 | ||
| Factors associated with D-dimer levels in HIV-infected individuals | Q35120065 | ||
| Estrogen receptors regulate innate immune cells and signaling pathways | Q35236340 | ||
| Select host restriction factors are associated with HIV persistence during antiretroviral therapy | Q35271996 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | human immunodeficiency virus infectious disease | Q18556697 |
| RNA virus infectious disease | Q18967413 | ||
| Retroviridae infectious disease | Q19000689 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 20706 | |
| P577 | publication date | 2016-02-18 | |
| P1433 | published in | Journal of the International AIDS Society | Q6296158 |
| P1476 | title | Barriers to a cure for HIV in women | |
| P478 | volume | 19 |
| Q56517281 | Analysis of complement-mediated lysis of SIV and SIV-infected cells reveals sex differences in vaccine-induced immune responses in Rhesus macaques |
| Q39366791 | Barriers to HIV remission research in low- and middle-income countries. |
| Q93147329 | Gender differences in innate responses and gene expression profiles in memory CD4 T cells are apparent very early during acute simian immunodeficiency virus infection |
| Q56762706 | International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK |
| Q90241137 | Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366 |
| Q60434051 | Pharmacology of Antiretrovirals in the Female Genital Tract for HIV Prevention |
| Q92456846 | Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting |
| Q46049688 | Research on HIV cure: Mapping the ethics landscape |
| Q92702667 | Revisiting the 'sterilising cure' terminology: a call for more patient-centred perspectives on HIV cure-related research |
| Q90348296 | Screening and Enrollment by Sex in HIV Clinical Trials in the United States |
| Q58104425 | Sex-Based Differences in HIV-1 Reservoir Activity and Residual Immune Activation |
Search more.